CDMO Companies in India — 50+ Contract Manufacturers (2026)

Introduction

If you have ever searched for the right CDMO partner in India, you understand how overwhelming it can feel to scroll through what appears to be a never-ending list of companies and certifications. The good news is India's pharma ecosystem is filled with capable and experienced CDMOs that range from small niche labs to large-scale manufacturing on par with the largest global pharma companies.

This quick guide will save you hours of searching! We have compiled a list of over 50 qualified Contract Development and Manufacturing Organizations (CDMOs) across India known for their quality, compliance, and will establish a strong partnership with clients from other countries.

Why India Has So Many Great CDMO Options

India is not in this position by chance, it is by design. Over the last 20 years, the country has invested heavily in R&D infrastructure, trained chemists and engineers, and established a track record of meeting global quality standards. Currently, there are over 600 FDA-approved manufacturing sites in India, the most of any country outside of the U.S. It is no surprise one can find early formulation work all the way to commercial scale-up under one-roof at often very favorable prices compared to the West. (Source: USFDA List of Indian Approved Facilities)

If you’re exploring outsourcing, India isn’t just an option anymore — it’s the default starting point.

List: 50+ Top CDMO Companies in India

Below is a mix of large integrated players and niche specialists. Each of them offers something unique — whether it’s biologics, injectables, small molecules, or formulation development.

Full-Service CDMOs (Discovery to Commercial Scale)

Piramal Pharma Solutions
Jubilant Biosys
Syngene International
GVK Bio (now Aragen Life Sciences)
Sai Life Sciences
Laurus Labs
Dishman Carbogen Amcis
Suven Pharmaceuticals
Biocon Biologics
Aurobindo Pharma

Formulation Development & Manufacturing Experts

Granules India
Dr. Reddy’s Custom Pharma Services
Hetero Drugs
Strides Pharma Science
Sun Pharmaceutical Industries (Contract Division)
Natco Pharma
MSN Laboratories
Torrent Pharma
Alembic Pharmaceuticals
Zydus Lifesciences

API & Intermediate Specialists

Divi’s Laboratories
SMS Lifesciences
Neuland Laboratories
Vasudha Pharma
Shilpa Medicare
Teva API India
Lupin Limited (API Division)
Solara Active Pharma Sciences
Aarti Drugs
Ipca Laboratories

Biotech, Biologics & Advanced Therapy CDMOs

Biocon Biologics
Intas Pharmaceuticals (Biotech Division)
Serum Institute of India
Panacea Biotec
Bharat Biotech
Stelis Biopharma
Gennova Biopharmaceuticals
Virchow Biotech
Biological E. Limited
Cadila Healthcare Biotech

Specialty & Emerging CDMOs

VAV Life Sciences
Anthem Biosciences
TCG Lifesciences
Richcore Lifesciences
Incozen Therapeutics
Sai Mirra Innopharm
Lambda Therapeutic Research
Encube Ethicals
Gufic Biosciences
Hikal Limited
Sequent Scientific
Akums Drugs & Pharmaceuticals Ltd
Biodeal Pharmaceuticals Ltd
Concord Biotech

(Tip: For small molecule projects, companies like Sai Life Sciences and Syngene are favorites among Western biotechs. For vaccines or biologics, Biocon and Serum Institute remain top choices.)

Global & Strategic Partners in India

International organizations with significant operations or partnerships in India:

WuXi STA — Expanded network offering small and large molecule services.
Thermo Fisher Scientific (Patheon) — Provides global CDMO services leveraging Indian infrastructure.
Lonza & AGC Biologics — Active in biologics manufacturing and viral vector production through collaborations.

Key Trends influencing CDMO Procurement Strategies in 2026

The Factors Driving Growth

The proportion that India contributes to the worldwide CDMO sector is projected to rise dramatically by 2028 and beyond due to low costs as well as a qualified labour force coupled with an abundance of financial incentives from the Government of India. In addition to diversifying to get away from China, changing conditions in the global supply chain are also creating new outsourcing possibilities for Indian CDMOs.

Innovation in Therapeutics

There has been an explosion in investment in pharmacogenomics and targeted protein therapeutics resulting in the expansion of service offerings of the world's top CDMO companies.

Regulatory Compliance & Quality Assurance

The compliance frameworks established by the food regulation agencies of the United States and Europe (i.e. USFDA, EMA, PIC/S) are among the most critical factors that pharmaceutical companies take into consideration when deciding from which CDMO to source their products. As Indian CDMOs gain and maintain compliance with these agencies, it will increase the percentages of business being done with them.

How to Choose the Right CDMO Partner in India

Before you engage with anyone, spend a matter of minutes even, determining your requirements. India has enough depth to manage nearly any project, but your needs will indicate what you value.

Verify track records in regulatory — USFDA, EMA, or MHRA are most prominent (Read: How Indian CDMOs Comply with USFDA, EU-GMP, and WHO-GMP Standards)
Confirm capacity and turnaround times — Some CDMOs are bottlenecked.
Determine IP policies — Indian CDMOs work with strong IP protection, but it's still prudent to review agreements carefully.
Communication Workflow — The best partners respond promptly, and give precise technical updates.
Ask for case studies or a client reference — Nothing is better than transparency.

Where These CDMOs Are Located

You’ll find CDMO clusters in key regions:

Hyderabad: APIs, biologics, and large-scale manufacturing.
Ahmedabad & Vadodara: Long-standing pharma manufacturing base.
Bengaluru: Discovery, CRO/CDMO hybrids, and biotech startups.
Pune & Mumbai: Formulation and analytical specialists.
Visakhapatnam: API clusters, export manufacturing

Each city has strong supply chain support, experienced talent, and easy access to ports — which means smooth logistics for exports.

The Bottom Line

The Indian CDMO landscape in 2026 features a rich mix of established players, emerging innovators, global collaborators, and capacity expansion stories. Whether you’re a small biotech seeking formulation support or a global pharma scaling commercial supply, you’ll find an Indian partner ready to collaborate — often faster and more flexibly than you’d expect. To know about sourcing apis from India, read How to Source GMP-Certified APIs from India – Compliance & Supplier Guide

Need Support with Sourcing APIs from Verified Manufacturers?

Share your API requirement — molecule, quantity, target market, and dossier needs — and we’ll connect you with verified, capability-matched manufacturers across India, China, Europe, the USA, and emerging hubs, along with technical confirmations and quotations.

Submit your API sourcing request

Third party manufacturing or full CDMO service — which do you actually need?

Buyers approaching CDMOs in India often use "third party manufacturing", "contract manufacturing" and "CDMO" as though they mean the same thing. They do not, and choosing the wrong arrangement costs time and money.

Third party manufacturing — an existing product, manufactured to your specification and packed under your brand and label. The formulation and dossier already exist. This is the fastest route to market and the most common arrangement for distributors and marketing companies building a portfolio.
Contract manufacturing (CMO) — manufacturing to your process and specification, typically where you already hold the technology or dossier and need capacity.
Full CDMO service — development as well as manufacturing: formulation development, analytical method development, stability studies, bioequivalence where required, and dossier preparation in CTD, EU-CTD or ACTD format. Necessary when the product does not yet exist in the form you need, or when you need a dossier you can file in your own name.

The practical test is straightforward: if a suitable product already exists and you only need it made and packed for you, third party manufacturing is enough. If you need something developed, or you need to own a dossier, you need a CDMO.

What actually makes Indian CDMOs worth using — and how to evaluate them

Two things drive the case for manufacturing in India, and they should be assessed together rather than separately.

1. Cost structure

Indian manufacturing costs are materially lower than equivalent capacity in the United States or Europe, across labour, utilities, plant construction and validation. For generics and off-patent products competing on price, this is frequently the difference between a project that works commercially and one that does not. Minimum order quantities also tend to be lower than at tier-1 global platforms, which makes single-market launches and smaller portfolios viable.

But cost alone is a poor basis for selection. Low pricing with no explanation of the underlying cost structure is a warning sign, not a bargain.

2. Plant approvals — and this is the part buyers get wrong

The value of an Indian CDMO is not the company's reputation. It is which specific plant holds which approval.

A site holding EU-GMP or USFDA approval adds substantial value beyond access to those markets. It signals that the facility has been inspected against the strictest standards, that quality systems, documentation practices and data integrity have been externally examined, and that the manufacturer can withstand scrutiny. Buyers supplying semi-regulated markets often find that a product made at an EU-GMP or USFDA-approved site registers more smoothly and carries more credibility with their own customers and regulators, even where those approvals are not formally required.

The critical detail: approvals attach to facilities and product lines, never to companies. A large Indian manufacturer may hold USFDA approval at one plant, EU-GMP at another, and only WHO-GMP at a third. Being told "we are a USFDA-approved company" tells you nothing about the site that will make your product.

What to establish before proceeding:

Which plant will manufacture your product — by name and address, not the corporate headquarters
Which approvals that specific plant holds — WHO-GMP, EU-GMP, USFDA, ANVISA, TGA, PMDA — and the date of the most recent inspection
Whether the approval covers your dosage form at that site; a plant approved for oral solids is not approved for injectables
Recent inspection outcomes — any Form 483 observations, warning letters or import alerts, and how they were closed out. A manufacturer that discusses this openly is usually the safer partner
Verification against the issuing authority — EudraGMDP for EU-GMP, the FDA inspection database for USFDA. Certificates should be checked, not accepted

Taken together, cost-effectiveness combined with a genuinely approved plant is what makes Indian contract manufacturing compelling. Cost without approvals is a false economy; approvals without cost advantage remove the reason for sourcing from India in the first place.

Frequently asked questions about CDMOs in India

How many CDMO companies are there in India?

India hosts several hundred contract development and manufacturing organisations, ranging from small speciality formulation developers to large integrated groups operating multiple approved plants. This guide lists over 50 established CDMOs in India across full-service, formulation, API and biologics categories. India also hosts the largest number of USFDA-compliant manufacturing facilities outside the United States.

Which are the top CDMO companies in India?

The leading CDMOs in India span several categories rather than a single ranking: full-service organisations covering discovery through commercial supply, formulation development and manufacturing specialists, API and intermediate producers, and biologics and advanced-therapy providers. The right choice depends on your dosage form, target market and volume rather than on company size. The listing above groups CDMOs in India by capability for exactly this reason.

What is the difference between a CDMO and third party manufacturing in India?

Third party manufacturing means an existing product is manufactured and packed under your brand — the formulation and dossier already exist. A CDMO additionally provides development services: formulation development, analytical methods, stability studies, bioequivalence where required, and dossier preparation. If you need a product developed or a dossier you can file in your own name, you need a CDMO. If a suitable product already exists, third party manufacturing is faster and cheaper.

Why do international buyers source contract manufacturing from India?

Cost structure and plant approvals together. Indian manufacturing costs are materially lower than equivalent US or EU capacity, and minimum order quantities are typically lower than at tier-1 global platforms. At the same time, India hosts the largest number of USFDA-compliant facilities outside the United States, and many sites hold EU-GMP approval. A plant holding EU-GMP or USFDA approval carries value well beyond those markets, because it demonstrates the facility has withstood the strictest regulatory inspection.

How do I verify an Indian CDMO's GMP certification?

Ask for the certificate for the specific manufacturing site that will produce your product, then verify it against the issuing authority's records — EudraGMDP for EU-GMP, the FDA inspection database for USFDA, or the relevant national regulator. Confirm the approval covers your dosage form at that site and that it is current. Approvals are site-specific and product-specific, never company-wide, so a company-level claim should never be accepted on its own.

What minimum order quantities do Indian CDMOs accept?

MOQs vary by manufacturer, dosage form and whether the order is stock supply or a dedicated manufacturing batch. Indian CDMOs generally accept lower minimums than tier-1 global platforms, which makes single-market launches and smaller portfolios viable. A credible volume forecast for the following twelve to thirty-six months usually secures better terms than a larger one-off order, because manufacturing economics are driven by line occupancy rather than by the first purchase order.

Can Indian CDMOs supply dossiers for my market?

Many Indian manufacturers hold ready dossiers in CTD, EU-CTD or ACTD format, frequently with bioequivalence data already completed. Where a dossier exists and can be licensed, market entry compresses from years to months. Establish before contracting whether the dossier can be filed in your name, whether it is exclusive to you, and what happens to it on termination — dossier ownership causes more disputes than any other contractual term.

How long does it take to start manufacturing with an Indian CDMO?

For an existing product under a third party manufacturing arrangement, technology transfer and first commercial supply typically take a few months. Where formulation development, bioequivalence studies and a fresh dossier are required, expect eighteen months to three years depending on dosage form and target market. Sterile injectables generally take longer than oral solids, and available capacity — rather than price — is often the binding constraint.

Frequently Asked Questions(FAQs)

1. What is a CDMO?

A CDMO delivers outsourced development and manufacturing for pharmaceuticals. This includes both drug products, Drug Substance (API), drug product formulation, clinical trial (study) or commercial quantities of drug product manufacturing.

2. Why choose India for CDMO services?

The top reason to choose India as a CDMO provider is the low cost of labor and an abundance of highly skilled resources, the availability of well-established production facilities that meet the requirements of both the FDA and the EMA, and the rapid growth in India as a leading provider of biologicals and other complex molecules.

3. What services do Indian CDMOs offer?

Indian-based CDMOs provide a variety of services, including API manufacturing, formulation development, clinical trial (study) material supply, commercial manufacturing, sterile fill finished products, and additional advanced manufacturing technologies such as antibody-drug conjugates (ADCs) and biologics.

4. Are Indian CDMOs globally compliant?

Yes, most of the leading CDMO’s (Contract Development Manufacturing Organizations) in India are compliant with GxP (Good Practice) guidelines set forth by agencies globally, including the USFDA, the EMA, the (Medicines and Healthcare products Regulatory Agency) MHRA and the World Health Organization GMP guidelines.

5. Who uses Indian CDMOs?

Indian CDMOs are an excellent choice for many pharmaceutical companies including large multinational pharmaceutical manufacturers, biotechnology/biopharmaceutical startup companies, generic pharmaceutical producers and specialty pharma companies, throughout the entire development pipelines of their products.

6. How to choose a CDMO partner?

When selecting a CDMO partner, reviewing each company's regulatory approvals, therapeutic expertise, development-to-commercialization capabilities, quality record, scalability and cost competitiveness is recommended.

7. Fastest-growing CDMO segments in India?

Some of the fastest growing segments within the CDMO industry in India today are biologicals, peptides, highly potent APIs (active pharmaceutical ingredients), ADCs (antibody drug conjugates), and complex injectables.

50+ Leading CDMO Companies in India for Pharma Sourcing